PE20020953A1 - Benzotiadiazina como inhibidores de metaloproteinasas de matriz - Google Patents

Benzotiadiazina como inhibidores de metaloproteinasas de matriz

Info

Publication number
PE20020953A1
PE20020953A1 PE2002000109A PE2002000109A PE20020953A1 PE 20020953 A1 PE20020953 A1 PE 20020953A1 PE 2002000109 A PE2002000109 A PE 2002000109A PE 2002000109 A PE2002000109 A PE 2002000109A PE 20020953 A1 PE20020953 A1 PE 20020953A1
Authority
PE
Peru
Prior art keywords
inhibitors
benzotiadiazine
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
PE2002000109A
Other languages
English (en)
Inventor
Michael William Wilson
Joseph Armand Picard
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PE20020953A1 publication Critical patent/PE20020953A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Manufacture Of Alloys Or Alloy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A DERIVADOS DE BENZOTIADIAZINA DE FORMULA I DONDE n ES 0-2; X ES O, NH; R2 ES H, ALQUILO C1-C6, R1 Y R3 SON H, ACILO, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, (CH2)mARILO, (CH2)mHETEROARILO, (CH2)mCICLOALQUILO, M es 0-6; R3 NO ES (CH2)mBIFENILO, (CH2)mCICLOALQUILO,. SON COMPUESTOS PREFERIDOS ESTER BENCILICO DE ACIDO 2-BENCIL-4-METIL-1,1,3-TRIOXO-1,2,3,4-TETRAHIDRO-1L6-BENZO[1,2,4]TIADIAZINA-7-CARBOXILICO; BENCILAMIDA DEL ACIDO 2-BENCIL-4-METIL-1,1,3-TRIOXO-1,2,3,4-TETRAHIDRO-1L6-BENZO[1,2,4]TIADIAZINA-7-CARBOXILICO, (PIRIDIN-4-IL-METIL)-AMIDA DE ACIDO 2-BENCIL-4-METIL-1,1,3-TRIOXO-1,2,3,4-TETRAHIDRO-1L6-BENZO[1,2,4]TIADIAZINA-7-CARBOXILICO, ENTRE OTROS LOS COMPUESTOS SON INHIBIDORES DE METALOPROTEINASAS DE MATRIZ Y PUEDEN SE RUTILES APRA ELT RATAMIENTO DEL CANCER, ARTRITIS REUMATOIDE, OSTEOARTRITIS, FALLO CARDIACO CONGESTIVO
PE2002000109A 2001-02-14 2002-02-12 Benzotiadiazina como inhibidores de metaloproteinasas de matriz PE20020953A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26878201P 2001-02-14 2001-02-14

Publications (1)

Publication Number Publication Date
PE20020953A1 true PE20020953A1 (es) 2002-10-25

Family

ID=23024450

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000109A PE20020953A1 (es) 2001-02-14 2002-02-12 Benzotiadiazina como inhibidores de metaloproteinasas de matriz

Country Status (17)

Country Link
US (1) US6656932B2 (es)
EP (1) EP1368327B1 (es)
JP (1) JP2004518726A (es)
AT (1) ATE280164T1 (es)
BR (1) BR0207865A (es)
CA (1) CA2433075A1 (es)
DE (1) DE60201665T2 (es)
DO (1) DOP2002000336A (es)
ES (1) ES2231708T3 (es)
GT (1) GT200200016A (es)
HN (1) HN2002000227A (es)
MX (1) MXPA03005870A (es)
PA (1) PA8538501A1 (es)
PE (1) PE20020953A1 (es)
TN (1) TNSN02013A1 (es)
UY (1) UY27155A1 (es)
WO (1) WO2002064578A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
JP4164028B2 (ja) 2001-10-12 2008-10-08 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アルキンマトリックスメタロプロテイナーゼ阻害剤
US6747147B2 (en) 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
BR0312943A (pt) * 2002-07-17 2005-07-12 Warner Lambert Co Combinação de um inibidor alostérico de matriz metaloproteinase-13 com um inibidor seletivo de ciclooxigenase-2 que não é celecoxib ou valdecoxib
WO2004006914A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
CA2495432A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
CA2492379A1 (en) * 2002-07-17 2004-01-22 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AU2003249539A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
AU2003250466A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
JP2006501215A (ja) 2002-08-13 2006-01-12 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテイナーゼ阻害剤としての単環式誘導体
EP1530472A1 (en) * 2002-08-13 2005-05-18 Warner-Lambert Company LLC Isoquinoline derivatives as matrix metalloproteinase inhibitors
ES2283851T3 (es) 2002-08-13 2007-11-01 Warner-Lambert Company Llc Derivados de pirimidin-2,4-diona como inhibidores de las metaloproteinasas de matriz.
AU2003249531A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
EP1537090A1 (en) * 2002-08-13 2005-06-08 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
AU2003249477A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003250475A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
WO2004014377A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors
AU2003250470A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014916A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004014909A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
WO2004014365A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
WO2004014388A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
US7247654B2 (en) 2003-06-04 2007-07-24 Bristol-Myers Squibb Company 3,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitors
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
US20060247231A1 (en) * 2003-12-18 2006-11-02 Warner-Lambert Company Llc Amide and ester matrix metalloproteinase inhibitors
US7570259B2 (en) 2004-06-01 2009-08-04 Intel Corporation System to manage display power consumption
ES2310861T3 (es) 2004-12-08 2009-01-16 Bristol-Myers Squibb Company Compuestos heterociclicos como inhibidores del factor viia.
CA2602609A1 (en) 2005-03-16 2006-09-21 Junichi Yokotani Novel anthranilic acid derivative or salt thereof
HRP20171415T4 (hr) * 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
US9034867B2 (en) 2011-03-18 2015-05-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
JP6471089B2 (ja) 2012-03-19 2019-02-13 アルカームス ファーマ アイルランド リミテッド 脂肪酸エステルを含む医薬組成物
JP6219918B2 (ja) 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド グリセロールエステルを含む医薬組成物
CA2867137C (en) 2012-03-19 2020-12-08 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
MX2016012041A (es) 2014-03-20 2017-01-19 Alkermes Pharma Ireland Ltd Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion.
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略
CN111454232B (zh) * 2020-05-30 2021-11-23 南方医科大学 一种1,3,4-噻二嗪类化合物及其应用
CN113773277B (zh) * 2021-09-18 2023-12-05 兰州大学 一种4h-1,2,4-苯并噻二嗪-1,1-二氧化物衍生物的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242443B1 (en) * 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
IL128545A0 (en) * 1996-12-09 2000-01-31 Warner Lambert Co Method for treating and preventing heart failure and ventricular dilatation
WO1998049146A2 (en) * 1997-04-28 1998-11-05 The United States Of America, Represented By The Secretary Department Of Health & Human Services, The National Institutes Of Health Cyclin dependent kinase (cdk)4 inhibitors and their use for treating cancer
JPH11199512A (ja) 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
WO2001009485A1 (fr) 1999-07-30 2001-02-08 Yoshikane Ikitake Moteur a combustion interne rotatif equipe de palettes a mouvements alternatifs
PA8498701A1 (es) 1999-08-12 2002-08-26 Pfizer Prod Inc Pirimidina-2,4,6-trionas inhibidores de metaloproteinasas
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
EP1332136A2 (en) 2000-10-26 2003-08-06 Pfizer Products Inc. Pyrimidine-2,4,6-trione metalloproteinase inhibitors
HUP0301577A3 (en) 2000-10-26 2006-02-28 Pfizer Prod Inc Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz

Also Published As

Publication number Publication date
BR0207865A (pt) 2004-03-23
UY27155A1 (es) 2002-09-30
ATE280164T1 (de) 2004-11-15
TNSN02013A1 (fr) 2005-12-23
EP1368327B1 (en) 2004-10-20
DE60201665D1 (de) 2004-11-25
US6656932B2 (en) 2003-12-02
DE60201665T2 (de) 2006-02-02
CA2433075A1 (en) 2002-08-22
JP2004518726A (ja) 2004-06-24
GT200200016A (es) 2002-10-01
PA8538501A1 (es) 2002-09-17
US20020156069A1 (en) 2002-10-24
WO2002064578A1 (en) 2002-08-22
ES2231708T3 (es) 2005-05-16
DOP2002000336A (es) 2003-01-31
HN2002000227A (es) 2002-10-23
EP1368327A1 (en) 2003-12-10
MXPA03005870A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
PE20020953A1 (es) Benzotiadiazina como inhibidores de metaloproteinasas de matriz
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
ATE349435T1 (de) Dpiv-inhibitoren auf glutaminbasis
NO20072605L (no) Nytt antranilinsyrederivat eller et salt derav
BR0213010A (pt) Aminopirimidinas substituìdas com tiazolila como agentes de proteção de plantas
DE602004024880D1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
EA200500017A1 (ru) Новые соединения
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
PT94568A (pt) Quinazolinonas substituidas como antagonistas da angiotensina ii
NO953305D0 (no) Antranilsyrederivat
SG132672A1 (en) 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
ATE357434T1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
PA8509301A1 (es) Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en enfermedades inflamatorias, autoinmunes y respiratorias
EA200200976A1 (ru) Способ лечения или ингибирования полипов ободочной кишки
DE60002714D1 (de) Substituierte azaoxindolederivate
CY1108808T1 (el) Ενωσεις μοτιλιδης
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
CO5680420A2 (es) Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4
DE60221425D1 (de) Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase-inhibitoren
GT200200259A (es) Fungicidas
ATE505462T1 (de) Neue biologischaktive molekü le
DE602004031115D1 (de) Pyrimidinverbindungen mit phosphonatgruppen als antivirale nucleotidanaloga
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
EA200100040A1 (ru) Химический синтез морфолиновых производных
MXPA05004845A (es) N-oxidos y derivados de melfalan para el tratamiento de estados de enfermedad asociados a un factor inducible por hipoxia.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed